Clinical Trials Logo

Clinical Trial Summary

FYU-981 or Benzbromarone are administrated to hyperuricemia patients with or without gout for 14 weeks to compare the efficacy and safety of these drugs by the method of multicenter, randomized, double-blind, ascending dose regimen.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT03100318
Study type Interventional
Source Fuji Yakuhin Co., Ltd.
Contact
Status Completed
Phase Phase 3
Start date April 1, 2017
Completion date August 31, 2018

See also
  Status Clinical Trial Phase
Completed NCT03372200 - Febuxostat-Controlled, Double-Blind, Comparative Study of FYU-981 in Hyperuricemia With or Without Gout Phase 3
Completed NCT03375632 - Study of FYU-981 in Hyperuricemic Outpatients With or Without Gout (Effect on Two Hyperuricemic Types) Phase 1
Completed NCT03006445 - Study of FYU-981 in Hyperuricemia With or Without Gout Phase 3